Interplay of miRNA-146a and miRNA-126 in Chronic Periodontitis Patients With Coronary Artery Disease

M

Meenakshi Ammal Dental College and Hospital

Status

Completed

Conditions

Coronary Artery Disease
miRNA
Chronic Periodontitis

Study type

Observational

Funder types

Other

Identifiers

NCT04583085
MADC/IRB-XXVI/2018/415

Details and patient eligibility

About

The role of micro-RNAs in chronic periodontitis associated with CAD is still in an incipient stage needs to be explored further. The investigators attempt to quantify and compare the levels of micro-RNA 146a and micro-RNA 126 in subgingival as well as coronary plaque samples obtained from patients diagnosed with chronic periodontitis with and without coronary artery disease.

Full description

The role of micro-RNAs in chronic periodontitis associated with CAD is still in an incipient stage needs to be explored further. The investigators attempt to quantify and compare the levels of micro-RNA 146a and micro-RNA 126 in subgingival as well as coronary plaque samples obtained from patients diagnosed with chronic periodontitis with and without coronary artery disease. Seventy-five participants were selected and grouped into 3 categories; 25 patients diagnosed with chronic periodontitis and coronary artery disease: CP + CAD group; 25 patients diagnosed with chronic periodontitis alone: CP group; and 25 systemically and periodontally healthy controls (HP). Demographic variables, periodontal parameters, cardiac parameters, blood pressure were obtained. miRNA-146a and miRNA126 levels were assessed in subgingival plaque (SP) samples from all the three groups. Within CP+CAD group, SP samples of CP+CADa were compared with coronary plaques samples (CP) of CP+CADb while the patient underwent CABG.

Enrollment

75 patients

Sex

Male

Ages

30 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients volunteering for the investigation.
  • Patients between the age group of 30-70 years
  • Presence of ≥ 15 natural teeth.

Exclusion criteria

  • Patients associated with systemic diseases such as lung disorders, renal disease, liver disease, type I, type II-diabetes mellitus, HIV infection, rheumatoid arthritis, allergy or any malignancy.
  • Under treatment with antibiotics, immunosuppressive drugs such as corticosteroids, within 6 months.
  • Pregnant women and female patients were excluded because of the altered oral flora due to hormonal changes
  • Smoking and other tobacco usage habits
  • Patients who underwent periodontal treatment within 6 months.

Trial design

75 participants in 3 patient groups

CP + CHD group
Description:
This was further divided into CP + CHDa (Subgingival plaque) and CP + CHDb (Coronary plaque) based on the nature of plaque collected.
CP group
Description:
25 patients with chronic periodontitis who were systemically healthy were selected
HP group
Description:
25 patients who were systemically and periodontally healthy, were considered as HP group.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems